Literature DB >> 18400142

Remifentanil-TCI and propofol-TCI for conscious sedation during fibreoptic intubation in the acromegalic patient.

T Cafiero1, F Esposito, G Fraioli, G Gargiulo, A Frangiosa, L M Cavallo, N Mennella, P Cappabianca.   

Abstract

BACKGROUND AND
OBJECTIVE: To evaluate the use of remifentanil-propofol administered as target-controlled infusion during awake fibreoptic intubation for anticipated difficult tracheal intubation in acromegalic patients.
METHOD: In all, 20 consecutive acromegalic patients underwent elective endonasal endoscopic transsphenoidal pituitary surgery. After premedication with midazolam 0.03 mg kg(-1), initially a target-controlled infusion of remifentanil 1.0 ng mL(-1) and propofol 1.5 microg mL(-1) was started. The fibreoptic intubation was performed by the same physician experienced with the fibreoptic technique. During the fibreoptic procedure the target concentrations of remifentanil and propofol ranged between 1.0 and 5.0 ng mL(-1), and between 1.5 and 3.5 microg mL(-1), respectively. Changes in heart rate and mean arterial pressure were recorded during airway manipulation, during tracheal intubation, and at 1 and 3 min after. On the first postoperative day, patient recall and level of discomfort during fibreoptic intubation were evaluated.
RESULTS: Endotracheal intubation was efficaciously and quickly secured in all patients. A significant increase in mean arterial pressure and heart rate was recorded only during tracheal intubation (P < 0.05). Oxygenation was sufficient and no bradypnea or apnoea was recorded. All patients later described their anaesthetic experience as satisfactory. During fibreoptic intubation, remifentanil (ng mL(-1)) and propofol (microg mL(-1)) mean effect-site concentrations were 3.2 +/- 0.3 and 2.0 +/- 1.0, respectively.
CONCLUSION: Remifentanil and propofol target-controlled infusion provided satisfactory conscious sedation allowing for successful oral fibreoptic intubation in acromegalic patients with no recall.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400142     DOI: 10.1017/S0265021508004195

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  7 in total

1.  Tramadol combined with fentanyl in awake endotracheal intubation.

Authors:  Sai-Ying Wang; Yang Mei; Hui Sheng; Yang Li; Rui Han; Cheng-Xuan Quan; Zhong-Hua Hu; Wen Ouyang; Zhao-Qian Liu; Kai-Ming Duan
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

2.  Dexmedetomidine versus remifentanil sedation during awake fiberoptic nasotracheal intubation: a double-blinded randomized controlled trial.

Authors:  Rong Hu; J X Liu; Hong Jiang
Journal:  J Anesth       Date:  2012-10-17       Impact factor: 2.078

3.  Subcutaneous dissociative conscious sedation (sDCS) an alternative method for airway regional blocks: a new approach.

Authors:  Mihan J Javid
Journal:  BMC Anesthesiol       Date:  2011-10-26       Impact factor: 2.217

4.  Comparison between remifentanil and dexmedetomidine for sedation during modified awake fiberoptic intubation.

Authors:  Hui-Hui Liu; Tao Zhou; Jian-Qi Wei; Wu-Hua Ma
Journal:  Exp Ther Med       Date:  2015-02-13       Impact factor: 2.447

5.  Dexmedetomidine versus remifentanil for sedation during awake intubation using a Shikani optical stylet: a randomized, double-blinded, controlled trial.

Authors:  Ting Xu; Min Li; Cheng Ni; Xiang-Yang Guo
Journal:  BMC Anesthesiol       Date:  2016-08-02       Impact factor: 2.217

6.  Efficacy of Adding Low-Dose Ketamine to Dexmedetomidine Versus Low-Dose Ketamine and Propofol for Conscious Sedation in Patients Undergoing Awake Fiber-optic Intubation.

Authors:  Reem Abdelraouf El Sharkawy
Journal:  Anesth Essays Res       Date:  2019 Jan-Mar

7.  A systematic review and meta-analysis of the safety and efficacy of remifentanil and dexmedetomidine for awake fiberoptic endoscope intubation.

Authors:  Zhi-Hang Tang; Qi Chen; Xia Wang; Nan Su; Zhengyuan Xia; Yong Wang; Wu-Hua Ma
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.